期刊文献+

高效液相色谱法测定人血浆中茴拉西坦活性代谢产物ABA及其在生物等效性研究中的应用 被引量:1

Determination of active metabolite of aniracetam ABA in human plasma by HPLC and its bioequivalence in healthy volunteers
下载PDF
导出
摘要 目的建立人血浆中茴拉西坦代谢产物N-对甲氧基苯甲酰胺基丁酸(ABA)的高效液相色谱法,并研究其在健康人体的生物等效性。方法以氢氯噻嗪为内标,血浆样品用液液-萃取处理。分析柱为SymmetryShield RP18C18(3.9 mm×150 mm,5μm),柱温:30℃。流动相:20 mmol.L-1甲酸胺-甲醇(83∶17,v/v),流速:1.0 mL.min-1,进样量:20μL,紫外检测波长250 nm。结果茴拉西坦活性代谢产物ABA的线性范围为53.313 640μg.L-1,最低定量下限为53.3μg.L-1;日内、日间RSD不超过11%;平均回收率为96.9%103.3%。结论该方法专属性强,快速、灵敏,适合血样中茴拉西坦代谢产物ABA的浓度检测。 Objective To establish a method to determine active metabolite of aniracetam ABA concentration in the plasma by HPLC and study its bioequivalence in healthy volunteers.Methods Hydrochlorothiazide was used as the internal standard,and ABA in the plasma sample was determined by HPLC with liquid-liquid extraction,and achieved by the column of SymmetryShield RP18 C18(3.9 mm×150 mm,5 μm)at 30 ℃.The mobile phase consisted of 20 mmol·L-1 ammonium formate-methanol= 83∶17(v/v) at 1.0 mL·min-1.The injection volume was 20 μL.The UV detection wavelength was 250 nm.Results The method was linear within 53.3-13 640 μg·L-1 for ABA,and the lowest detectable concentration was 53.3 μg·L-1.The intra-day and inter-day precision was no more than 11%.The recovery was 96.9%-103.3%.Conclusion The method is accurate and sensitive with no interference,which is suitable for the determination of active metabolite of aniracetam ABA in human plasma.
作者 罗健 马虹英
出处 《中南药学》 CAS 2010年第10期739-742,共4页 Central South Pharmacy
关键词 茴拉西坦 N-对甲氧基苯甲酰氨基丁酸 高效液相色谱 血药浓度 生物等效性 aniracetam ABA HPLC plasma concentration bioequivalence
  • 相关文献

参考文献10

二级参考文献26

  • 1金永寿.新促智药茴拉西坦(Aniracetam)[J].国外医药(合成药.生化药.制剂分册),1994,15(6):337-340. 被引量:12
  • 2姜慧芳,陈斌艳,魏志军,梁欣,程能能,李雪宁.茴拉西坦胶囊在中国健康志愿者体内的生物等效性[J].中国临床药学杂志,2005,14(3):155-158. 被引量:5
  • 3邵东.阿尼西坦及其胶囊的HPLC测定[J].中国医药工业杂志,1995,26(7):324-325. 被引量:2
  • 4崔秀生.高效液相色谱法分析血清中微量阿尼西坦[J].首都医科大学学报,1996,17(2):130-132. 被引量:1
  • 5Taro Ogiso,Masahiro Iwaki,Tadatoshi,Tanino,et al.Pharmacokinetics of aniracetam and its metabolites in rats[J].Journal of Pharmaceutical Science,1998,87 (5):594-598.
  • 6Guenzi A,Zanetti M.Determination of aniracetam and its main metabolites,N-anisoyl-GABA,in human plasma by high-performance liquid chromatography[J].Journal of Chromatography,1990,(530):397-406.
  • 7[1]Guenzi A, Zanetti M.Determination of anriacetam and its main metabolite ,N-anisoyl-GABA,in human plasma by highperformance liquid chromatography.J Chromatography,1990;530:397~406.
  • 8[2]Taro O,Masahiro I,Tadatoshi T, et al. Pharmacokinetics of aniracetam and its metabolites in rats.J Pharmaceutical Sciences,1998;87:594~601.
  • 9Canonico V, Forgione L, Paoletti C, et al. Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration[J]. Riv Neurol, 1991, 61(3):92~96.
  • 10Endo H, Tajima T, Yamada H, et al. Pharmacokinetics study of aniracetam in elderly patients with cerebral vascular disease[J].Behav Brain Res, 1997,83:243~244.

共引文献21

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部